SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Inozyme Pharma, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - May 16, 2025) - Rigrodsky Law, P.A. is investigating Inozyme Pharma, Inc. ("Inozyme") (NASDAQ: INZY) regarding possible breaches of fiduciary duties and other violations of law related to Inozyme's agreement to be acquired by BioMarin Pharmaceutical Inc. Under the terms of the agreement, Inozyme shareholders will receive $4.00 per share in cash.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-inozyme-pharma-inc.

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call (302) 295-5310 or email [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252453

You May Also Be Interested In

• Apple faces £2bn UK lawsuit over app tracking rules
• NVIDIA to acquire Hugging Face for $12.93 billion
• Magna Terra Announces Upsize of Private Placement to $3.75 Million